Listing shares on the NASDAQ under the symbol RETA, Reata Pharmaceuticals priced its IPO at $11 per share, below its expected range of $14 to $16. The sale valued Reata at $236.5 million. The company develops treatments that modulate the activity of key regulatory proteins associated with a variety of life-threatening diseases. Reata had raised venture capital from investors including Novo (16.4% pre-IPO stake) and AbbVie (10.3%). The stock closed its first day of trading at $13.07.